British company Small Pharma is leading the first regulated trial for psychedelic therapies which could treat conditions such as depression. Thanks to Brexit, a number of companies have been approved to test the unusual and radical treatments under new rules drawn up after the UK left the EU.
The trials will involve 42 people with depression and will follow a phase-one trial in healthy volunteers.
Thanks to Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) created an “Innovative Licensing and Access Pathway (ILAP)” that allows for a speedier process to test medicines and deliver them to patients.
The patients will receive a 20-minute psychedelic experience which can include hallucinations, to be followed by a two-hour therapy session.
The news comes as the UK is taking the EU to court as it has been blocking access to international science programmes, including the £80billion Horizon Europe. Under the Trade and Cooperation Agreement (TCA ), it was agreed that Britain would take part in Horizon, Copernicus and Euratom.
“In all logic, trying to exclude British scientists from the Horizon programme will damage Europe enormously and is a self-defeating objective.
“It is also quite wrong to link these things, which they are not allowed to do in trade terms at all.”
Sir Iain added: “They fuss when anything happens to them but they are very quick to take the law into their own hand.
“The truth is, the Government has a very strong case.”